Abstract:Cardiovascular disease remains a leading cause of morbidity and mortality among Americans. A significant share of all resources for health care is allocated for the diagnosis and treatment of acute coronary syndrome (ACS), including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. Because millions of patients visit emergency departments with chest pain and other symptoms that might indicate ACS, the clinician must be familiar with appropriate diagnostic and therapeutic treatment measures. Non-ST-segment elevation (NSTE) ACS is a particularly challenging clinical entity due in part to limitations in the diagnostic tools employed to detect it and the wide range of therapeutic options available to treat it. Despite advances in the treatment of ACS and the dissemination of formal recommendations on approaches to managing NSTE ACS, pharmacologic and reperfusion therapy remain underused and often delayed. This results in an increase in adverse cardiac events for patients and rising health care costs for the public. The key to NSTE ACS management is rigorous adherence and application of evidence-based recommendations. The American Heart Association (AHA) and the American College of Cardiology (ACC) have released comprehensive clinical practice guidelines to manage NSTE ACS. These include a process of risk stratification of patients presenting with NSTE ACS or possible NSTE ACS. Risk stratification can be performed using a number of scoring models, including the Thrombolysis in Myocardial Infarction (TIMI), the Global Registry of Acute Coronary Events (GRACE), and the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) scoring models. Once a patient's risk for adverse cardiac events is determined, appropriate diagnostic and therapeutic modalities can be selected to match their level of risk. American College of Cardiology/AHA recommendations for the diagnosis and treatment of NSTE ACS include considerations regarding admission, antiplatelet therapy, anticoagulation, and early percutaneous coronary intervention/diagnostic angiography with the intent to perform revascularization. New information has emerged since the release of the 2007 updated ACC/AHA guidelines. The 2009 update of the ACC/AHA guidelines includes new recommendations on antiplatelet therapy, early invasive therapy, and the timing of glycoprotein IIb/IIIa inhibitor therapy for patients with NSTE ACS. Considering this new information during the application of the ACC/AHA guidelines will enhance selecting the optimal treatment for the NSTE ACS patient and ensure appropriate use of health care resources.

Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice

Antiplatelet and Anticoagulation Treatment in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Comparison of the Updated North American and European Guidelines

Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines

Approach to non-ST-segment elevation acute coronary syndrome in the emergency department: risk stratification and treatment strategies

An update on management of the patient presenting with non-ST-elevation acute coronary syndromes

2018 Update of Expert Consensus Statement on Antiplatelet Therapy in East Asian Patients with ACS or Undergoing PCI

Clinical Analysis of 373 Patients with Non-ST Elevation Acute Coronary Syndrome in a Teaching Hospital

Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes

Evolving management of ST-segment elevation myocardial infarction: update on recent data

Anticoagulants in ischemia-guided management of non-ST-elevation acute coronary syndromes

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016

Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

[The differences between the guidelines of the European Society of Cardiology and the American College of Cardiology/ American Heart Association for oral P2Y12 inhibitor therapy in the management of patients with acute coronary syndromes]

A Critical Appraisal of the 2023 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndrome

Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation

The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting

ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction

Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS)

Updates on Acute Coronary Syndrome: A Review

Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective

Practical implications of ACC/AHA 2007 guidelines for the management of unstable angina/non-ST elevation myocardial infarction